PROKIDNEY CORP. reports a Return on Equity (ROE) of 7.31%.

What is PROK's dividend yield?

PROKIDNEY CORP. offers a dividend yield of 0.00%.

What is PROK's Quality Score?

Our AI rates PROK's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PROK?

Our AI Timing Score for PROK is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PROK belong to?

PROKIDNEY CORP. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

PROK (NASDAQ) Stock Analysis | PROKIDNEY CORP.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

PROK AI Analysis Summary

Our AI summary for PROK: PROKIDNEY CORP. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 7.31%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PROK

PROKIDNEY CORP.

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 1.54

-0.04 (-2.53%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

7.3%

ROE

-25.6%

ROA

0.00%

Div Yield

PROKIDNEY CORP.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.54 Price -0.04 (-2.53%) Day Change	NEWS SCORE: 99

PROK, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.54
PBV / Sector	1.81 / 5.20
Earning Per Share	-0.24

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	1.77 M GREAT
Average 1W Daily Value	1.26 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-8,418.00 / 98.71
NPM Average (%) / Sector	-32,217.03 / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-25.56 / 27.02
ROA Average (%) / Sector	-17.86 / -368.17
ROA Change Average (%) / Sector	19.36 / 5,404.12 GOOD
ROE (%) / Sector	7.31 / 3.47
ROE Average (%) / Sector	6.67 / 6.51
ROE Change Average (%) / Sector	10.51 / 2,128.13 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:21
Symbol	PROK
Name	PROKIDNEY CORP.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	205.20 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	477.25 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States, 27103

Phone: 336 999 7019

Website: https://prokidney.com

Employees: 231

Sector: Healthcare >> Biotechnology

Description: ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.